TC BioPharm (Holdings) Ltd - TCBP STOCK NEWS

TC BioPharm (TCBP) has announced significant operational restructuring initiatives focused on outsourcing and cost reduction. The company plans to transition to a CDMO model for production to meet future clinical trial demands and explore new manufacturing facilities with automated technologies.

The restructuring involves a workforce reduction of approximately 20 employees, primarily in production and quality divisions, representing about half of the company's total headcount. These changes will be completed by the end of Q2 2025.

The initiative is expected to reduce core operational burn rate by 55% compared to 2024, with estimated partial year 2025 savings of $2.1 million and annualized savings of $4.2 million. The company frames this strategic shift as preparation for ACHIEVE data review and expansion into new indication verticals while reducing in-house expenses.

TC BioPharm (TCBP) has announced a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company through an all-stock transaction. The target company has an FDA-approved once-daily eye drop for treating glaucoma and ocular hypertension, currently being distributed to 300 physicians for sample treatments.

The acquisition aligns with TCBP's M&A strategy to expand its therapeutic platform and incorporate later-stage assets. The target company's product is expected to generate meaningful revenue in 2025, targeting a market projected to exceed $8 billion in a single patient population. TCBP anticipates executing the binding letter of intent within 2-3 weeks and closing the acquisition in Q3 2025.

The global glaucoma market, valued at $8.06 billion in 2022, is projected to reach $12.69 billion by 2032. This acquisition represents TCBP's transformation from a focused developer to a diversified therapeutics company.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced its CEO Bryan Kobel's upcoming participation in the Cancer Progress Panel at the 18th Annual European Life Sciences CEO Forum.

The panel discussion is scheduled for February 27th, 2025, at 1:10 pm CET at the Hilton Zurich Airport Hotel. The forum, taking place on February 26-27, 2025, will feature over 12 hours of high-level keynotes and panel discussions, including HealthTech topics such as AI, convergence, and diagnostics.

The event will showcase more than 50 presentations from public, private, emerging, and seed companies seeking investment and partnering opportunities in innovative healthcare solutions.

TC BioPharm (TCBP) has announced the completion of Cohort A dosing in its ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 for acute myeloid leukemia (AML) and myelodysplastic syndromes. The preliminary results show promising outcomes with no drug-related adverse events and evidence of stable disease in several patients following multiple TCB008 infusions.

Cohort A, which was re-initiated in July 2024, targeted patients ineligible for or who had exhausted all available therapies. The trial utilized higher doses of TCB008, containing up to a billion Gamma Delta T-Cells. While Cohort A enrollment has concluded, recruitment for Cohort B continues. The company reports expedited data delivery, occurring just six months after study re-initiation.

TC BioPharm (TCBP) announced successful completion of initial Cohort B patient dosing in the ACHIEVE Phase 2B clinical trial, evaluating TCB008 for Acute Myeloid Leukemia (AML). The first Cohort B patient received all four planned doses, totaling approximately 819 million Gamma Delta T-cells, with a fifth dose expected.

The ACHIEVE trial, an open-label Phase II study, evaluates TCB008's efficacy and safety in patients with AML and myelodysplastic syndromes (MDS/AML). Cohort B specifically targets patients in remission but with detectable minimal residual disease (MRD). Recruitment began in Q4 2024, ahead of schedule, with the first patient dosed in October 2024.

Preliminary data shows no drug-related adverse events following cumulative infusions of up to a billion cells, supporting TCB008's positive safety profile. The company expects to complete Cohort B enrollment in H1 2025, with data readout anticipated later in the year.

TC BioPharm (NASDAQ: TCBP) announced a significant change in its American Depositary Shares (ADS) ratio, effective February 10, 2025. The ratio will shift from 1 ADS representing 200 ordinary shares to 1 ADS representing 4,000 ordinary shares. This adjustment effectively implements a 1-for-20 reverse ADS split.

The change requires ADS holders to exchange every 20 ADSs for 1 new ADS, with The Bank of New York Mellon managing the exchange process. No ordinary shares will be issued or canceled, and TCBP will continue trading on Nasdaq Capital Market. Fractional new ADSs will be aggregated and sold, with net proceeds distributed to affected holders.

While the ADS trading price is expected to increase proportionally, the company provides no guarantees regarding the post-change trading price relationship.

TC BioPharm (NASDAQ: TCBP) announced plans to initiate Proof of Concept preclinical studies for its lead therapeutic TCB008 to treat H5N1 (Bird Flu). The company is seeking university partnerships to accelerate preclinical work needed for Phase I studies. TCB008 is an allogeneic, unmodified cell therapy composed of activated and expanded gamma delta T cells, which the company believes could help address the emerging avian bird flu epidemic.

The announcement follows the first reported U.S. death from H5N1 by the Louisiana Department of Health. H5N1 is a viral infection typically contracted through contact with infected birds but can spread between humans, with symptoms appearing within 2-8 days, resembling common flu symptoms and potentially carrying high mortality rates in humans.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced its participation in the upcoming Sequire Investor Summit 2025. The company's CEO, Bryan Kobel, will deliver a corporate overview presentation at the event, which is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer and other conditions, has announced the continuous trading of its American Depository Shares (ADSs) on the Nasdaq Global Select Market under the ticker symbol 'TCBP'. The company confirmed there has been no interruption in trading, and shares are expected to continue trading without disruption.